"Designing Growth Strategies is in our DNA"
Non-radiographic axial spondyloarthritis (nr-axSpA) is an autoimmune disorder which leads to arthritis of the pelvis and spine. Radiographic sacroiliitis is not exhibited by patients with non-radiographic axial spondylolysis. Stiffness and pain in the back, fatigue, pain in tendons & ligaments, and pain underneath the foot, and at the front of the chest are some of the symptoms associated with non-radiographic axial spondyloarthritis that usually begins between the age 15-45 years.
The blood test used to check for the presence of a gene HLA-B27 and imaging techniques such as MRI scan are methods used for the diagnosis of non-radiographic axial spondyloarthritis. According to National Ankylosing Spondylitis (NASS), it was estimated that around 7 in 10 people with nr-axSpA exhibit visible inflammation in the spine during MRI process and no inflammation would be exhibited by 3 in 10 people with non-radiographic axial spondyloarthritis. Physiotherapy and non-steroidal anti-inflammatory drugs are the first line of therapy for the treatment of non-radiographic axial spondylolysis that helps in the reduction of the pain associated with it. Additionally, biologic therapy is a relatively new treatment that could be very effective in the treatment of non-radiographic axial spondyloarthritis.
Many pharmaceutical companies have been focusing on studying and developing new treatment options for non-radiographic axial spondyloarthritis. For instance; Secukinumab, which is being studied by Novartis AG, is currently in phase-3 clinical trials for Study of Efficacy and Safety of Secukinumab in Patients with Non-radiographic axial spondyloarthritis
To know how our report can help streamline your business, Speak to Analyst
At present, around 69% of the pipeline candidates for Non-radiographic Axial Spondyloarthritis are in the phase-3 stage. More than half of the studies are sponsored by industry.
Report Description
The report on ‘Non-Radiographic Axial Spondyloarthritis – Pipeline Review, 2019’ provides a comprehensive overview of the drugs that are in the R&D pipeline by indication or molecule for Non-Radiographic Axial Spondyloarthritis. The report provides a thorough analysis of the distribution of the pipeline products by clinical trial stage, indication, company, therapy area and details such as clinical trial stage, sponsor, description on every product in the pipeline. Products in the preclinical and clinical stage along with dormant & discontinued pipeline candidates are included in the report. The report also covers additional insights such as epidemiology overview and current market scenario for Acromegaly.
The report on ‘Non-radiographic Axial Spondyloarthritis – Pipeline Review, 2019’, which is built by following a robust research methodology involving primary interviews and desk research, provides a complete overview of the R&D activity and pipeline products to assist companies in developing growth strategies and identifying emerging players.
Report Scope
Report Methodology
Reasons to Buy this Report